Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to food intake, stimulating insulin release and suppressing glucagon release. GLP-1 agents exhibit promising therapeutic efficacy in treating type 2 diabe